- Home
- GBX vs PCRX Comparison
GBX vs PCRX Comparison
Compare GBX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- PCRX
- Stock Information
- Founded
- GBX 1974
- PCRX 2006
- Country
- GBX United States
- PCRX United States
- Employees
- GBX N/A
- PCRX 790
- Industry
- GBX Railroads
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- PCRX Health Care
- Exchange
- GBX Nasdaq
- PCRX Nasdaq
- Market Cap
- GBX 1.4B
- PCRX 1.2B
- IPO Year
- GBX N/A
- PCRX 2011
- Fundamental
- Price
- GBX $47.15
- PCRX $26.45
- Analyst Decision
- GBX Hold
- PCRX Buy
- Analyst Count
- GBX 2
- PCRX 6
- Target Price
- GBX $59.50
- PCRX $30.00
- AVG Volume (30 Days)
- GBX 268.1K
- PCRX 666.0K
- Earning Date
- GBX 10-22-2025
- PCRX 08-05-2025
- Dividend Yield
- GBX 2.74%
- PCRX N/A
- EPS Growth
- GBX 88.14
- PCRX N/A
- EPS
- GBX 7.10
- PCRX N/A
- Revenue
- GBX $3,533,700,000.00
- PCRX $705,848,000.00
- Revenue This Year
- GBX N/A
- PCRX $7.36
- Revenue Next Year
- GBX N/A
- PCRX $10.07
- P/E Ratio
- GBX $6.57
- PCRX N/A
- Revenue Growth
- GBX 0.70
- PCRX 2.25
- 52 Week Low
- GBX $37.77
- PCRX $12.61
- 52 Week High
- GBX $71.06
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- GBX 52.50
- PCRX 61.33
- Support Level
- GBX $45.44
- PCRX $25.14
- Resistance Level
- GBX $47.50
- PCRX $27.04
- Average True Range (ATR)
- GBX 1.02
- PCRX 0.82
- MACD
- GBX 0.14
- PCRX 0.07
- Stochastic Oscillator
- GBX 69.23
- PCRX 69.49
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.